Dopamine D2 receptor binding before and after treatment of major depression measured by [123I]IBZM SPECT

Psychiatry Research - Neuroimaging

Volumn 90, Issue 2, 1999, Pages 91-101

  Klimke, Ansgar ^a   Larisch, Rolf ^a   Janz, Astrid ^a   Vosberg, Henning ^a   Müller Gärtner, Hans Wilhelm ^a   Gaebel, Wolfgang ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

Basal ganglia; Cingulate cortex; Dopamine receptors; Iodobenzamide; Single photon emission computed tomography

Indexed keywords

DOPAMINE 2 RECEPTOR; FLUOXETINE; IODINE 123; N [(1 ETHYL 2 PYRROLIDINYL)METHYL] 3 IODO 6 METHOXYSALICYLAMIDE; 3 IODO 2 HYDROXY 6 METHOXY N ((1 ETHYL 2 PYRROLIDINYL)METHYL)BENZAMIDE; 3-IODO-2-HYDROXY-6-METHOXY-N-((1-ETHYL-2-PYRROLIDINYL)METHYL)BENZAMIDE; ANXIOLYTIC AGENT; BENZAMIDE DERIVATIVE; BENZODIAZEPINE DERIVATIVE; CONTRAST MEDIUM; PAROXETINE; PYRROLIDINE DERIVATIVE; SEROTONIN UPTAKE INHIBITOR;

ADULT; AGED; ARTICLE; BRAIN SCINTISCANNING; CINGULATE GYRUS; CLINICAL ARTICLE; DEPRESSION; DOPAMINERGIC SYSTEM; DRUG RECEPTOR BINDING; FEMALE; HUMAN; ISOTOPE LABELING; MALE; PRIORITY JOURNAL; RECEPTOR OCCUPANCY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; CASE CONTROL STUDY; CORPUS STRIATUM; DRUG COMBINATION; DRUG EFFECT; MAJOR DEPRESSION; METABOLISM; SCINTISCANNING;

ADULT; AGED; ANTI-ANXIETY AGENTS; BENZAMIDES; BENZODIAZEPINES; CASE-CONTROL STUDIES; CONTRAST MEDIA; CORPUS STRIATUM; DEPRESSIVE DISORDER, MAJOR; DRUG THERAPY, COMBINATION; FEMALE; FLUOXETINE; HUMANS; MALE; PAROXETINE; PYRROLIDINES; RECEPTORS, DOPAMINE D2; SEROTONIN UPTAKE INHIBITORS; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 0033606145     PISSN: 09254927     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0925-4927(99)00009-8     Document Type: Article

References (41)

1. Ågren H., Reibring L. PET studies of presynaptic monoamine metabolism in depressed patients and healthy volunteers. Pharmacopsychiatry. 27(1):1994;2-6.
2. DSM-IV: Diagnostic and Statistical Manual of Mental Disorders. 4th ed. 1994;American Psychiatric Press, Washington, DC.
3. Baldessarini R.J., Marsh E. Fluoxetine and side effects. Archives of General Psychiatry. 47:1990;191-192.
4. Bench C.J., Friston K.J., Brown R.G., Scott L.C., Frackowiak R.S., Dolan R.J. The anatomy of melancholia - focal abnormalities of cerebral blood flow in major depression. Psychological Medicine. 22(3):1992;607-615.
5. Booij J., Korn P., Linszen D.H., van Royen E.A. Assessment of endogenous dopamine release by methylphenidate challenge using iodine-123 iodobenzamide single-photon emission tomography. European Journal of Nuclear Medicine. 24(6):1997;674-677.
6. 2 receptor imaging with SPECT: studies in different neuropsychiatric disorders. Journal of Cerebral Blood Flow and Metabolism. 11:1991;220-228.
7. Caine S., Koob G.F. Modulation of cocaine self-administration in the rat through D-3 dopamine receptors. Science. 260(5115):1993;1814-1816.
8. Chalon S., Guimbal C., Guilloteau D., Mayo W., Huguet F., Schmitt M.H., Desplanches G., Baulieu J.L., Besnard J.C. Iodobenzamide for in vivo exploration of central dopamine receptors: evaluation in animal models of supersensitivity. Life Sciences. 47:1990;729-734.
9. Del Zompo M., Bocchetta A., Bernadi F., Burrai C., Corsini G.U. Clinical evidence for a role of the dopaminergic system in depressive syndromes. Gessa G.L., Serra G. Dopamine and Mental Depression. 1990;177-184 Pergamon Press, Oxford.
10. Dewey S.L., Smith G.S., Logan J., Alexoff D., Ding Y.S., King P., Pappas N., Brodie J.D., Ashby C.R. Jr. Serotonergic modulation of striatal dopamine measured with positron emission tomography (PET) and in vivo microdialysis. Journal of Neuroscience. 15:1995;821-829.
11. 2 receptors in depression measured with single photon emission computed tomography. Biological Psychiatry. 35:1994;128-132.
12. 2 receptor blockade in depression before and after sleep deprivation - preliminary results. Biological Psychiatry. 35(11):1994;880-885.
13. Greitz T., Bohm C., Holte S., Eriksson L. A computerized brain atlas: construction, anatomical content, and some applications. Journal of Computer Assisted Tomography. 15:1991;26-38.
14. Kapur S., Mann J.J. Role of the dopaminergic system in depression. Biological Psychiatry. 32:1992;1-17.
15. Kinney J.L. Nomifensine maleate: a new second-generation antidepressant. Clinical Pharmacology. 4:1985;625-636.
16. 3H-spiperone to dopaminergic receptors. Advances in the Biosciences. 77:1990;159-166 Pergamon, Oxford.
17. 123I]iodobenzamide SPECT study. British Journal of Psychiatry. 171:1997;574-577.
18. 123I]IBZM: a potential CNS D-2 dopamine receptor imaging agent. Journal of Nuclear Medicine. 30:1989;88-92.
19. 2 receptors in striatum and anterior cingulate gyrus in major depression. Neuroimage. 5(4):1997;251-260.
20. Larisch R., Schulte K.W., Vosberg H., Ruzicka T., Müller-Gärtner H.W. Differential accumulation of iodine-123-iodobenzamide in melanotic and amelanotic melanoma metastases in vivo. Journal of Nuclear Medicine. 39(6):1998;996-1001.
21. Maj J., Rogoz Z., Skuza G., Söwinska H. Antidepressants given repeatedly increase the behavioral effect of D-2 agonist. Journal of Neural Transmission: General Section. 78:1989;1-8.
22. 3 receptors: effects of ions and guanine nucleotides. Journal of Pharmacology and Experimental Therapeutics. 274(4):1995;790-797.
23. 76Br-bromolisuride. British Journal of Psychiatry. 158:1991;346-350.
24. 2 receptors and negative symptoms of schizophrenia. British Journal of Psychiatry. 164:1994;27-34.
25. 4 receptors. European Journal of Pharmacology. 290(1):1995;29-36.
26. Moreau J.-L., Jenck F., Martin J.R., Mortas P., Haefely W.E. Antidepressant treatment prevents chronic unpredictable mild stress-induced anhedonia as assessed by ventral tegmental self-stimulation behavior in rats. European Neuropsychopharmacology. 2:1992;43-49.
27. 2 receptors in mesostriatal regions of the human forebrain. Proceedings of the National Academy of Sciences of the United States of America. 91(23):1994;11271-11275.
28. Muscat R., Papp M., Willner P. Reversal of stress-induced anhedonia by the atypical antidepressants, fluoxetine and maprotiline. Psychopharmacology. 109:1992;433-438.
29. 2 receptor binding in limbic forebrain associated with chronic mild stress-induced anhedonia and its reversal by imipramine. Psychopharmacology. 115(4):1994;441-446.
30. 2 receptors in animal models: iodobenzamide and iodoethylspiperone. Life Sciences. 52:1993;1851-1860.
31. 2 dopamine receptor binding in the basal ganglia of antipsychotic-free schizophrenic patients. British Journal of Psychiatry. 164:1994;16-26.
32. Randrup A., Munkvad I., Fog R., Gerlach J., Molander L., Kjellberg B., Scheel-Krüger J. Mania, depression and brain dopamine. Essman W.B., Valizelli L. Current Developments in Psychopharmacology. 2:1975;206-248 Spectrum, New York.
33. 123I-iodobenzamide single photon emission computed tomography in the drug-naive state and after neuroleptic treatment. Biological Psychiatry. 43(9):1998;660-665.
34. Seeman P., Bzowej N., Guan H.C., Bergeron C., Becker L.E., Reynolds G.P., Bird E.D., Riederer P., Jellinger K., Watanabe S. Human brain dopamine receptors in children and aging adults. Synapse. 1:1987;399-404.
35. 2 receptors in human subjects with iodine-123-IBZM. Journal of Nuclear Medicine. 33:1992;1964-1971.
36. Thomas D.R., Nelson D.R., Johnson A.M. Biochemical effects of the antidepressant paroxetine, a specific 5-hydroxytryptamine uptake inhibitor. Psychopharmacology. 93:1987;193-200.
37. van Praag H.M., Korf J., Lakke J.P.W.F., Schut T Dopamine metabolism in depressions, psychoses and Parkinson's disease: the problem of the specificity of biological variables in behavioral disorders. Psychological Medicine. 5:1975;138-146.
38. Willner P., Towell A., Sampson D., Sophokleous S., Muscat R. Reduction of sucrose preference by chronic mild stress and its restoration by a tricyclic antidepressant. Psychopharmacology. 93:1987;358-364.
39. Willner P., Muscat R., Papp M., Sampson D. Dopamine, depression and anti-depressant drugs. Willner P., Scheel-Krüger J. The Mesolimbic Dopamine System: From Motivation to Action. 1991;387-410 John Wiley, New York.
40. Willner P., Lappas S., Cheeta S., Muscat R. Reversal of stress-induced anhedonia by the dopamine receptor agonist, pramipexole. Psychopharmacology. 115(4):1994;454-462.
41. Wong D.F., Wagner H.N., Dannals R.F., Links J.M., Frost J.J., Ravert H.T., Wilson A.A., Rosenbaum A.E., Gjedde A., Douglass K.H. Effects of age on dopamine and serotonin receptors measured by positron tomography in the living human brain. Science. 226:1984;1391-1396.